“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.
In this video, Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, discusses the main points of the lecture, “LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer,” presented recently at the 2021 Prostate Cancer Foundation Scientific Retreat.
The FDA is currently reviewing a new drug application (NDA) for the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. A decision on the NDA is scheduled to be made in the first half of 2022.
Hofman is a nuclear medicine physician and director of PROSTIC, Melbourne, Australia.